Guardant Health (NASDAQ:GH) and Celcuity (NASDAQ:CELC) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, profitability, analyst recommendations and valuation.

Analyst Ratings

This is a breakdown of current recommendations for Guardant Health and Celcuity, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Guardant Health 0 0 6 0 3.00
Celcuity 0 0 2 0 3.00

Guardant Health currently has a consensus target price of $83.50, indicating a potential upside of 7.81%. Celcuity has a consensus target price of $35.50, indicating a potential upside of 66.04%. Given Celcuity’s higher probable upside, analysts plainly believe Celcuity is more favorable than Guardant Health.

Earnings & Valuation

This table compares Guardant Health and Celcuity’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Guardant Health $90.64 million 74.44 -$85.06 million ($2.80) -27.66
Celcuity N/A N/A -$7.48 million ($0.74) -28.89

Celcuity has lower revenue, but higher earnings than Guardant Health. Celcuity is trading at a lower price-to-earnings ratio than Guardant Health, indicating that it is currently the more affordable of the two stocks.


This table compares Guardant Health and Celcuity’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Guardant Health N/A N/A N/A
Celcuity N/A -27.08% -26.15%

Insider and Institutional Ownership

68.5% of Guardant Health shares are held by institutional investors. Comparatively, 22.0% of Celcuity shares are held by institutional investors. 43.5% of Celcuity shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.


Guardant Health beats Celcuity on 6 of the 10 factors compared between the two stocks.

About Guardant Health

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications. It also provides LUNAR-1 for minimal residual disease and recurrence detection in cancer survivors. In addition, the company is developing LUNAR-2 for early detection of cancer in higher risk individuals. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.

About Celcuity

Celcuity Inc., a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the clinical outcomes of cancer patients treated with targeted therapies in the United States. The company's CELx diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. It is developing CELx HSF test to diagnose two new sub-types of HER2-negative breast cancer. The company is also developing CELx MP test to diagnose 12 new potential cancer sub-types in breast, lung, colon, ovarian, kidney, and bladder cancers. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with's FREE daily email newsletter.